Search results for "controlled"

showing 10 items of 2729 documents

Articaine versus lidocaine inferior alveolar nerve block in posterior mandible implant surgeries: a randomized controlled trial

2023

Background: The aim of this study is to compare the effects of %4 articaine and %2 lidocaine on inferior alveolar nerve block (IANB) for implant surgery in the posterior mandible.Material and Methods: The patients who have inserted implants in the posterior mandible were divided into 2 groups for IANB: lidocaine and articaine. VAS = visual analog scale, pain during surgery and injection, lip numb-ness time, mandibular canal-implant apex distance, age, gender, bone density, implant number, release incision, adjacent teeth, and duration of surgery were analyzed using t-test, Mann-Whitney U test, Spearman's coefficient, and, Pearson's chi-squared test. This trial followed the recommendations o…

Double-Blinddouble blind procedureEpinephrinemandibular nerveAnesthesia DentalExtractionlocal anesthetic agentCarticaineMandiblepain perceptionAdrenalineHypesthesiamapping reviewAnesthetic EfficacyDouble-Blind Methodle fortHumanshumanblood lossrandomized controlled trial (topic)Anesthetics LocalBuccal InfiltrationGeneral DentistryUNESCO:CIENCIAS MÉDICASRandomized Controlled Trials as Topicrelapsedental implantorthognathic surgery4-Percent ArticaineLidocainePulpitisNerve BlockMolarinfectionOtorhinolaryngologyarticaine2-Percent LidocaineSurgerylocal anesthesiadental anesthesiaMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Mesoporous inorganic nanoscale particles for drug adsorption and controlled release.

2018

The review provides an overview of the mesoporous inorganic particles employed as drug delivery systems for controlled and sustained release of drugs. We have classified promising nanomaterials for drug delivery on the basis of their natural or synthetic origin. Nanoclays are available in different morphologies (nanotubes, nanoplates and nanofibers) and they are typically available at low cost from natural resources. The surface chemistry of nanoclays is versatile for targeted modifications to control loading and release properties. Synthetic nanomaterials (imogolite, laponite and mesoporous silica) present the advantages of well-established purity and availability with size features that …

Drug CarriersMaterials sciencePharmaceutical ScienceNanoparticleImogoliteNanotechnology02 engineering and technologyMesoporous silica010402 general chemistry021001 nanoscience & nanotechnologySilicon Dioxide01 natural sciencesControlled release0104 chemical sciencesNanomaterialsNanofiberDelayed-Action PreparationsDrug deliveryClayHumansNanoparticlesAdsorption0210 nano-technologyMesoporous materialPorosityTherapeutic delivery
researchProduct

The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunc…

2005

The efficacy and safety of short-term immunotherapy with molecular standardized allergens (STI) has been demonstrated by double-blind placebo-controlled clinical trials. The aim of this study was to compare STI with symptomatic drug treatment.Forty-eight patients with rhinoconjunctivitis to grass and/or rye pollen were treated either with STI (ALK(7), n = 24) plus anti-allergic drugs or anti-allergic drugs, alone (n = 24) in a prospective, randomized study. Symptoms and use of drugs were reported in patient diaries and titrated nasal provocation and skin prick tests were performed at baseline, before, and after season.Median overall symptom (P = 0.022, U test) and medication scores (P = 0.0…

DrugAdultMalemedicine.medical_specialtyNasal Provocation TestsAdolescentmedia_common.quotation_subjectmedicine.medical_treatmentProvocation testRespiratory System AgentsPoaceaeNasal provocation testlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineotorhinolaryngologic diseasesMedicineHumansProspective Studies030223 otorhinolaryngologyProspective cohort studymedia_commonDesensitization (medicine)Conjunctivitis AllergicSkin Testsbusiness.industryRhinitis Allergic SeasonalImmunotherapyAntigens PlantMiddle AgedClinical trialTreatment OutcomeOtorhinolaryngologyDesensitization Immunologic030220 oncology & carcinogenesisImmunologyHistamine H1 AntagonistsSurgeryFemalebusinessFollow-Up StudiesOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
researchProduct

Modified Montmorillonite as Drug Delivery Agent for Enhancing Antibiotic Therapy

2021

The appealing properties of surfactant-intercalated Montmorillonites (Organo-montmorillonite, OMt) were successfully investigated to propose an effective drug delivery system for metronidazole (MNE) antibiotic therapy. This represents a serious pharmaceutical concern due to the adverse drug reactions and the low targeting ability of MNE. The non-ionic surfactant Tween 20 was used to functionalize montmorillonite, thus accomplishing the two-fold objective of enhancing the stability of clay dispersion and better controlling drug uptake and release. The adsorption process was performed under different experimental conditions and investigated by constructing the adsorption isotherms through hig…

DrugBiocompatibilitymedia_common.quotation_subjectmontmorillonite; organoclay; metronidazole; surfactant; adsorption; release; drug delivery systemDrug delivery systemGeologyMineralogyGeotechnical Engineering and Engineering GeologyControlled releasechemistry.chemical_compoundMontmorilloniteAdsorptionchemistryPulmonary surfactantChemical engineeringMetronidazoleReleaseSurfactantDrug deliveryOrganoclayAdsorptionOrganoclayQE351-399.2Montmorillonitemedia_commonMinerals; Volume 11; Issue 12; Pages: 1315
researchProduct

Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.

2019

Abstract A colon targeted drug delivery system for inflammatory bowel diseases (IBD), consisting in budesonide loaded mesoporous silica microparticles functionalized with a selective azo-molecular gate (M-Bud), has been evaluated for in vivo efficacy. Experimental colitis in male Wistar rats was induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). M-Bud was orally administered to the rats as a suspension in water. Colon/body weight ratio, clinical activity score, and histological evaluation were used as inflammatory indices to measure the performance of the microparticles. The formulation was compared with a suspension prepared from the commercial drug Entocord®. Sta…

DrugBudesonideMalemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivomedicineAnimalsColitisBudesonideTnbs colitismedia_commonChemistryMesoporous silica021001 nanoscience & nanotechnologymedicine.diseaseColitisSilicon DioxideControlled releasedigestive system diseasesRatsTargeted drug deliveryTrinitrobenzenesulfonic Acid0210 nano-technologyAzo Compoundsmedicine.drugInternational journal of pharmaceutics
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.

2014

Literature data pertaining to the decision to allow a waiver of in vivo bioequivalence (BE) testing requirements for the approval of immediate release (IR) solid oral dosage forms containing fluconazole as the only active pharmaceutical ingredient (API) are reviewed. The decision is based on solubility, dissolution, permeability, therapeutic index, pharmacokinetic parameters, pharmacodynamic properties, and other relevant data. BE/bioavailability (BA) problems and drug-excipients interaction data were also reviewed and taken into consideration. According to the biopharmaceutics classification system (BCS), fluconazole in polymorphic forms II and III is a BCS class I drug and has a wide ther…

DrugMalemedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyBioequivalenceDosage formPermeabilityBiopharmaceuticsExcipientsPharmacokineticsmedicineHumansFluconazolemedia_commonRandomized Controlled Trials as TopicActive ingredientDosage FormsCross-Over StudiesChemistryBiopharmaceutics Classification SystemBioavailabilitySolubilityTherapeutic EquivalencyFemaleFluconazolemedicine.drugJournal of pharmaceutical sciences
researchProduct

In VitroRelease of Local Anaesthetic and Anti-Inflammatory Drugs from Crosslinked Collagen Based Device

2012

The drug delivery systems that are the object of this article take the form of a hydrophilic matrix (collagen or crosslinked collagen) containing a drug. These devices can be used as The model active agents, were chosen from the range of local anaesthetics (lidocaine hydrochloride), anti-inflammatory (diclofenac sodium salt) and antioxydant (caffeic acid). Whatever the drug affinity for water, in the first time of the experiments, the release appears to be systematically delayed when the matrix is crosslinked. For lidocaine hydrochloride based systems, as the amount of drug increases in the matrix, the high gap concentration between the matrix and the buffer solution promote the diffusion a…

DrugMaterials scienceChromatographyPolymers and Plasticsmedia_common.quotation_subjectfood and beveragesGeneral ChemistryDiclofenac SodiumLidocaine HydrochlorideBuffer solutionControlled releaseMatrix (chemical analysis)chemistry.chemical_compoundchemistryDrug deliveryMaterials ChemistryCeramics and CompositesOrganic chemistrySolubilitymedia_commonJournal of Macromolecular Science, Part A
researchProduct

Immunomodulatory drugs: Oral and systemic adverse effects

2013

Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically investigated, however. Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective based on open literature search of the topic. Results: These target specific drugs appear to have less drug interactions than earlie…

DrugPathologymedicine.medical_specialtymedia_common.quotation_subjectPlacebo-controlled studyOdontologíaReviewBioinformaticsInflammatory bowel diseaselaw.inventionImmune systemRandomized controlled triallawmedicineHumansImmunologic FactorsAdverse effectGeneral Dentistrymedia_commonOral Medicine and PathologyLupus erythematosusbusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludstomatognathic diseasesOtorhinolaryngologyRheumatoid arthritisUNESCO::CIENCIAS MÉDICASSurgeryMouth DiseasesbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct